Charles River Laboratories vs Medpace
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Charles River Laboratories and Medpace side by side, using each one’s latest annual report. Here is what stands out:
- Charles River Laboratories is the larger business, with $4.0B of revenue in fiscal 2025 against $2.5B for Medpace, about 1.6 times as much.
- Medpace grew revenue faster (20.0%, against −0.9%).
- Medpace kept more of each dollar of sales as operating profit (21.1% operating margin, against 0.6%).
- Medpace turned more of its sales into free cash flow (27.0% FCF margin, against 12.9%).
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
Charles River Laboratories
CRL
0/9
Medpace
MEDP
8/9
Revenue growth5-year growthOperating marginNet marginFCF marginReturn on equityNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | CRL FY25 | MEDP FY25 |
|---|---|---|
| Size | ||
| Market cap | $17.1B | $19.2B |
| Revenue | $4.0B | $2.5B |
| Free cash flow | $518M | $682M |
| Net income | −$144M | $451M |
| Growth | ||
| Revenue growth | −0.9% | 20.0% |
| 5-year growth | 6.6% | 22.3% |
| Share count change | −4.0% | −7.8% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | 0.6% | 21.1% |
| Net margin | −3.6% | 17.8% |
| FCF margin | 12.9% | 27.0% |
| Return on capital | 0.4% | — |
| Return on equity | −4.4% | 70.2% |
| Balance sheet | ||
| Net debt | $1.9B | −$497M |
| Net debt / EBITDA | 4.5x | −0.9x |
| Dividends and buybacks | $361M | $917M |
| Valuation & quality | ||
| P/E | — | 37.6x |
| Piotroski F-score | 4 | 4 |
Ten years
Revenue
FY16
CRL $1.7B
MEDP $422M
FY17
CRL $1.9B
MEDP $436M
FY18
CRL $2.3B
MEDP $705M
FY19
CRL $2.6B
MEDP $861M
FY20
CRL $2.9B
MEDP $926M
FY21
CRL $3.5B
MEDP $1.1B
FY22
CRL $4.0B
MEDP $1.5B
FY23
CRL $4.1B
MEDP $1.9B
FY24
CRL $4.1B
MEDP $2.1B
FY25
CRL $4.0B
MEDP $2.5B
CRL
MEDP
Operating margin
FY16
CRL 14.1%
MEDP 12.5%
FY17
CRL 15.5%
MEDP 14.9%
FY18
CRL 14.6%
MEDP 14.3%
FY19
CRL 13.4%
MEDP 14.8%
FY20
CRL 14.8%
MEDP 18.0%
FY21
CRL 16.7%
MEDP 17.4%
FY22
CRL 16.4%
MEDP 19.1%
FY23
CRL 15.0%
MEDP 17.9%
FY24
CRL 5.6%
MEDP 21.2%
FY25
CRL 0.6%
MEDP 21.1%
CRL
MEDP
Free cash flow
FY16
CRL $262M
MEDP $78.2M
FY17
CRL $236M
MEDP $85.7M
FY18
CRL $301M
MEDP $141M
FY19
CRL $340M
MEDP $184M
FY20
CRL $380M
MEDP $227M
FY21
CRL $532M
MEDP $235M
FY22
CRL $295M
MEDP $351M
FY23
CRL $365M
MEDP $397M
FY24
CRL $502M
MEDP $572M
FY25
CRL $518M
MEDP $682M
CRL
MEDP
Return on capital
FY16
CRL 10.1%
MEDP 4.2%
FY17
CRL 7.5%
MEDP 6.2%
FY18
CRL 11.4%
MEDP 11.6%
FY19
CRL 9.8%
MEDP 16.4%
FY20
CRL 9.9%
MEDP 25.7%
FY21
CRL 11.1%
MEDP 35.1%
FY22
CRL 9.9%
MEDP 53.7%
FY23
CRL 8.9%
MEDP 78.7%
FY24
CRL 2.0%
MEDP 161.7%
FY25
CRL 0.4%
MEDP —
CRL
MEDP
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.